Showing results (81-90 of 97) with videos related to

Sort By:
Pageof 10
Journal of Acquired Immune Deficiency Syndromes (1999)|December 16, 2024
Weight and Metabolic Changes With Long-Acting Cabotegravir and Rilpivirine or Bictegravir/Emtricitabine/Tenofovir AlafenamideDarrell H S Tan, Andrea Antinori, Beng Eu, et al.
British Journal of Clinical Pharmacology|July 9, 2021
Multiparametric magnetic resonance imaging to characterize cabotegravir long-acting formulation depot kinetics in healthy adult volunteersBeat M Jucker, Edward J Fuchs, Sarah Lee, et al.
The Lancet. HIV|October 17, 2021
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR studyChloe Orkin, Enrique Bernal Morell, Darrell H S Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2023
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II TrialIan E Krop, Norikazu Masuda, Toru Mukohara, et al.
The Lancet. HIV|May 27, 2017
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trialMartin Markowitz, Ian Frank, Robert M Grant, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 21, 2023
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic FailureChloe Orkin, Jonathan M Schapiro, Carlo F Perno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2018
Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I TrialCostanza Paoletti, Gaia Schiavon, Emily M Dolce, et al.
Lancet (London, England)|July 29, 2017
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trialDavid A Margolis, Juan Gonzalez-Garcia, Hans-Jürgen Stellbrink, et al.
The Lancet. HIV|August 11, 2023
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trialMoti N Ramgopal, Antonella Castagna, Charles Cazanave, et al.
AIDS (London, England)|March 17, 2021
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysisAmy G Cutrell, Jonathan M Schapiro, Carlo F Perno, et al.
Pageof 10